TABLE 3.

The clinical performance of LA, cobas, LBC, or combinations of HPV genotypes detected by cobas and LBC for detection of AIN2 or AIN3 or AIN3 alone^a

Test and HPV statusb	Performance (%) of indicated test to detectc:
	AIN2 or AIN3 (n = 68)					AIN3 (n = 22)
	Se	Sp	YI	PPV	NPV	Se	Sp	YI	PPV	NPV
LA
HPV16	55.6	78.0	33.5	36.5	88.5	63.6	74.2	37.9	14.6	96.7
HPV18	19.0	91.3	10.4	33.3	83.2	13.6	89.6	3.3	8.3	93.8
HPV16 and HPV18	65.1	72.6	37.6	35.0	90.1	68.2	67.9	36.1	12.8	96.9
Any carcinogenic type	98.4	28.9	27.3	23.9	98.8	95.5	25.2	20.6	8.1	98.8
cobas
HPV16	57.4	74.4	31.7	34.5	88.1	63.6	70.4	34.1	12.39	96.7
HPV18	20.6	90.0	10.6	32.6	82.8	13.6	88.1	1.7	6.98	93.9
HPV16 and HPV18	66.2	67.8	34.0	32.6	89.5	68.2	63.3	31.5	10.87	96.8
Any carcinogenic type	100.0	26.0	26.0	24.1	100.0	100.0	22.4	22.4	7.80	100.0
LBC (T.M.D.)
ASC-US	83.6	51.1	34.6	28.9	92.9	90.5	46.6	37.1	9.8	98.7
HG	40.3	87.2	27.5	42.9	86.0	61.9	84.8	46.7	20.6	97.2
Genotypes and LBC (T.M.D.)
≥ASC-US or HPV16	92.5	42.7	35.2	27.9	96.0	95.2	37.8	33.1	9.0	99.2
≥ASC-US or HPV16/18	95.5	40.1	35.7	27.7	97.4	95.2	35.1	30.3	8.7	99.1
HG or HPV16	68.7	69.9	38.5	35.4	90.3	85.7	65.5	51.3	13.8	98.6
HG or HPV16/18	74.6	64.2	38.8	33.3	91.3	85.7	59.4	45.1	12.0	98.5

^aLBC, liquid-based cytology; AIN2, anal intraepithelial neoplasia grade 2; AIN3, anal intraepithelial neoplasia grade 3.

^bASC-US, atypical squamous cells of undetermined significance; ≥ASC-US, ASC-US or more severe cytology; HG, high-grade cytology (high-grade squamous intraepithelial lesion [HSIL] or atypical squamous cells cannot rule out HSIL [ASC-H] cytology).

^cSe, sensitivity; Sp, specificity; YI, Youden's index; PPV, positive predictive value.